Risk of disseminated tuberculosis and other infections after neonatal Bacillus Calmette–Guérin vaccination in infants with in-utero exposure to tumor necrosis factor-α inhibitors - Report - MDSpire
Advertisement
Risk of disseminated tuberculosis and other infections after neonatal Bacillus Calmette–Guérin vaccination in infants with in-utero exposure to tumor necrosis factor-α inhibitors
Evaluating the Risk of Disseminated Tuberculosis Following BCG Vaccination
Overview
This study assessed the safety of Bacillus Calmette–Guérin (BCG) vaccination at birth in infants exposed in utero to tumor necrosis factor-alpha (TNF-α) inhibitors. Findings indicate that BCG vaccination did not result in disseminated tuberculosis or increased risk of infections during the first year of life.
Background
Infants born to mothers treated with TNF-α inhibitors during pregnancy may face risks associated with immunosuppression, particularly concerning live vaccines like BCG. Recent guidelines recommend delaying live vaccinations in this population due to potential safety concerns. Understanding the implications of BCG vaccination in this context is crucial for optimizing infant health outcomes.
Data Highlights
Parameter
Value
Infants exposed to TNF-α inhibitors
63
Infants vaccinated with BCG
49 (77.8%)
Infants vaccinated at birth
27 (42.8%)
Infants with at least three infections
Over 50%
Cases of disseminated tuberculosis
0
Key Findings
63 infants were identified who were exposed to TNF-α inhibitors in utero.
77.8% of these infants received BCG vaccination within the first year of life.
42.8% of infants were vaccinated at birth, with most exposed during the third trimester.
Over half of the infants experienced at least three infections, but none developed disseminated tuberculosis.
Exposure to TNF-α inhibitors did not increase the risk of infection or hospitalization during infancy.
Clinical Implications
The findings support the safety of administering BCG vaccination at birth in infants exposed to TNF-α inhibitors, alleviating concerns regarding disseminated tuberculosis. Clinicians can consider this evidence when making vaccination decisions for this vulnerable population.
Conclusion
BCG vaccination at birth appears safe for infants exposed to TNF-α inhibitors in utero, with no cases of disseminated tuberculosis reported. This study contributes valuable data to the ongoing discussion about vaccination practices in this context.
